Zealand Pharma A/S and Iktos have announced a research collaboration to develop artificial intelligence (AI) technology for the design of peptide drugs. Iktos specializes in new drug design using AI, while Zealand Pharma is known for its peptide-based medicines.
Iktos’ AI technology is focused on creating new molecules with the qualities of potent medication. Recently, the company has expanded its research to include developing AI technology for peptide-based medicines, creating cutting-edge generative and predictive models for this purpose.
On the other hand, Zealand Pharma has a track record of success in developing innovative peptide-based pharmaceuticals. With years of experience in enhancing peptides’ medicinal properties, the company is eager to incorporate AI and machine learning into its computational chemistry tools for creating therapeutic peptides.
Under the collaboration agreement, Iktos will leverage Zealand’s expertise in peptide therapeutics to enhance its generative modeling technologies and AI skills. Yann Gaston-Mathé, President and CEO of Iktos, expressed excitement about working with Zealand Pharma to advance peptide generative and predictive modeling technology.
This partnership between Zealand Pharma and Iktos marks a significant step forward in the development of AI technology for peptide drug design, with the potential to revolutionize the field of peptide-based medicines.
